BP-C2 — Competitive Intelligence Brief

BP-C2 (BP-C2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

phase 2 ACE inhibitor ACE Cardiovascular Small molecule

Target snapshot

BP-C2 (BP-C2) — Meddoc. BP-C2 is a small molecule that targets the renin-angiotensin system to lower blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BP-C2 TARGET	BP-C2	Meddoc	phase 2	ACE inhibitor	ACE
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
Candesartan Cilexetil	CILEXETIL	Alembic	marketed		Ace Inhibitor	2021-01-01
Mylotarg	GEMTUZUMAB	Wyeth Pharms Inc	marketed	CD33-directed Immunoconjugate [EPC]	Myeloid cell surface antigen CD33	2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
2. Bioprojet · 2 drugs in this class
3. Ain Shams University · 2 drugs in this class
4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
6. Children's Hospital of Fudan University · 1 drug in this class
7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Ethicare GmbH · 1 drug in this class
10. Ace Cells Lab Limited · 1 drug in this class